-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II

Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)

Jonathan L. Kaufman, MD1, Hang Quach2, Rachid C. Baz, MD3, Annette Juul Vangsted, MD4*, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res5*, Simon J Harrison, MD6, Torben Plesner7, Philippe Moreau, MD8*, Simon D. Gibbs, MD9*, Eva Medvedova, MD10*, Muhammad Jalaluddin, PhD11*, Jeremy A. Ross, PhD11*, Leanne Lash Fleming, PhD11*, Yan Luo, MD, PhD11* and Nizar Jacques Bahlis, MD12

1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
2Clinical Haematology Service, St. Vincent’s Hospital, Melbourne, VIC, Australia
3Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL
4Dept. Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark
5Department of Haematology, St George Hospital, Sydney, Australia
6Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
7Department of Hematology, University of Southern Denmark and Vejle Hospital, Vejle, Denmark
8Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
9Department of Haematology, Monash University Eastern Health Clinical School, Melbourne, Australia
10Knight Cancer Institute, Oregon Health & Science University, Portland, OR
11AbbVie Inc., North Chicago, IL
12Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Sanjay R Mohan, MD, MSCI1, Cristiana Costa Chase, MD2, Jesus G Berdeja, MD3, Lionel Karlin4*, Karim Belhadj, MD5*, Aurore Perrot, MD, PhD6*, Philippe Moreau, MD7*, Cyrille Touzeau8*, Thomas Chalopin9*, Alexander M Lesokhin, MD10, Carol Ann Huff, MD11, David H. Vesole, MD, PhD12, Joshua Richter, MD13, Jeffrey V. Matous, MD14, Igor Proscurshim, MD15*, Eileen Wolff15*, Girish Gudi, PhD15*, Andrew Garton16*, Vinu Menon, PhD17*, Sunitha Gn, PhD18*, Yacine Salhi16*, Eric J. Feldman, MD16* and Mohamad Mohty, MD PhD19

1Department of Medicine, Division of Hematology-Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN
2Duke University, Durham, NC
3Department of Hematology, Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN
4Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Bénite, France
5Centre Hospitalier et Universitaire Henri Mondor, Creteil, France
6Hematology Department, University Hospital, Vandoeuvre Les Nancy, France
7Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
8University Hospital Hôtel Dieu, Nantes Cedex 1, FRA
9Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France
10Memorial Sloan Kettering Cancer Center, New York, NY
11Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
12Myeloma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ
13Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
14Colorado Blood Cancer Institute, Denver, CO
15Ichnos Sciences, New York, NY
16Ichnos Sciences, New York
17Glenmark Pharmaceuticals, Mumbai, India
18Glenmark Pharmaceuticals Limited, Mahape, India
19EBMT Paris study office / CEREST-TC, Paris, France, Department of Hematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Sorbonne University, Paris, France

Evangelos Terpos, MD, PhD1, Ioannis Ntanasis-Stathopoulos, MD1*, Maria Gavriatopoulou, MD2*, Panagiotis Malandrakis, MD2*, Despina Fotiou, MD2*, Nikolaos Kanellias, MD1*, Magdalini Migkou, MD2*, Foteini Theodorakakou, MD2*, Vasiliki Spiliopoulou, MD1*, Rodanthi Syrigou, MD1*, Evangelos Eleutherakis Papaiakovou, MD1*, Stavros Gkolfinopoulos, MD, MSc3*, Kyriaki Manousou, MSc3*, Efstathios Kastritis, MD4* and Meletios A. Dimopoulos, MD1

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
3Health Data Specialists, Dublin, Ireland
4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

Hang Quach1, Rajeev Rajagopal2*, Andrew Spencer3, Michael Low4*, Dickran Kazandjian, MD5, Rocco Crescenzo6*, Chenmu Du6*, Sheel Patel6*, Vaibhav Mundra6*, Huan Cheng6* and Binod Dhakal, MBBS7

1St. Vincents Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
2Middlemore Hospital, Auckland, New Zealand
3The Alfred Hospital, Melbourne, VIC, Australia
4Monash Health, Melbourne, VIC, Australia
5Sylvester Comprehensive Cancer Center, Miami, FL
6BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
7Medical College of Wisconsin, Milwaukee, WI

Meletios A. Dimopoulos, MD1, Evangelos Terpos, MD, PhD2, Mario Boccadoro, MD3, Sosana Delimpasi, MD4*, Meral Beksac5*, Eirini Katodritou, MD6*, Philippe Moreau, MD7*, Luca Baldini, MD8*, Argiris Symeonidis, MD, PhD9, Jelena Bila10*, Albert Oriol11*, Maria-Victoria Mateos, MD12, Hermann Einsele, MD13, Ioannis Orfanidis14*, Tobias Kampfenkel15, Weiping Liu16*, Michele Kosh17*, NamPhuong Tran18*, Robin Carson17 and Pieter Sonneveld, MD19

1National and Kapodistrian University of Athens, Athens, Greece
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
4Department of Hematology, Lymphoma and BMT Unit, Evangelismos Hospital, Athens, Greece
5Ankara University, Ankara, Turkey
6Department of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece
7Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
8UO Ematologia, Fondazione IRCCS Cà Granda, OM Policlinico, Università degli Studi, Milan, Italy
9Hematology Division, Department of Internal Medicine, University of Patras, Patras, Greece
10University Clinical Center of Serbia, Belgrade, Serbia
11Institut Català d’Oncologia and Institut Josep Carreras. Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
12University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
13Würzburg University Medical Centre, Würzburg, Germany
14Health Data Specialists S.A., Dublin, Ireland
15Janssen Research & Development, Neuss, Germany
16Janssen Research & Development, LLC, Shanghai, China
17Janssen Research & Development, LLC, Spring House, PA
18Janssen Research & Development, LLC, Los Angeles, CA
19Erasmus MC Cancer Institute, Rotterdam, Netherlands

Luciano J. Megala Costa, MD, PhD1, Saurabh Chhabra, MD, MS2, Eva Medvedova, MD3*, Timothy Martin Schmidt, MD4, Bhagirathbhai Dholaria, MBBS5, Kelly N. Godby, MD6*, Rebecca Silbermann, MD, MMS7, Susan Bal, MD8, Anita D'Souza, MD, MS9, Smith Giri, MD, MHS10, James L. Omel, MD11*, Parameswaran Hari, MD, MRCP12, Natalie Callander, MD13 and Binod Dhakal, MBBS14

1University of Alabama at Birmingham, Birmingham, AL
2Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3Knight Cancer Institute, Oregon Health & Science University, Portland, OR
4Carbone Cancer Center, University of Wisconsin, Madison, WI
5Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN
6Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL
7Knight Cancer Institute, Oregon Health and Science University, Portland, OR
8O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
9Division of Hematology Oncology, CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
10Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
11Myeloma Research Advocate/Advisor, Grand Island, NE
12Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
13University of Wisconsin Carbone Cancer Center, Madison, WI
14Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

Ajai Chari1*, Jonathan L. Kaufman, MD2, Jacob P Laubach, MD3*, Douglas W Sborov4*, Brandi Reeves, MD5, Cesar Rodriguez, MD6*, Rebecca Silbermann, MD, MMS7, Luciano J. Megala Costa, MD, PhD8, Larry D. Anderson Jr., MD, PhD9, Nitya Nathwani, MD10, Nina Shah, MD11, Naresh Bumma, MD12, Sarah A. Holstein, MD, PhD13, Caitlin Costello, MD14, Andrzej Jakubowiak, MD, PhD15, Tanya M. Wildes, MD13*, Robert Z. Orlowski, MD, PhD16, Kenneth H. Shain, MD, PhD17, Andrew J. Cowan, MD18*, Huiling Pei, PhD19*, Annelore Cortoos, MD20*, Sharmila Patel, PhD20*, Thomas S. Lin, MD, PhD20, Paul G. Richardson, MD21, Saad Usmani, MD22 and Peter M. Voorhees, MD23*

1Icahn School of Medicine at Mount Sinai, New York, NY
2Winship Cancer Institute of Emory University Hospital, Atlanta, GA
3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4University of Utah Huntsman Cancer Institute, Salt Lake City, UT
5University of North Carolina School of Medicine, Chapel Hill, NC
6Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
7Knight Cancer Institute, Oregon Health & Science University, Portland, OR
8University of Alabama at Birmingham, Birmingham, AL
9Myeloma, Waldenstrom’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
10Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
11University of California San Francisco, San Francisco, CA
12Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
13Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
14Moores Cancer Center, University of California San Diego, La Jolla, CA
15University of Chicago Medical Center, Chicago, IL
16Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
17Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
18Division of Medical Oncology, University of Washington, Seattle, WA
19Janssen Research & Development, LLC, Titusville, NJ
20Janssen Scientific Affairs, LLC, Horsham, PA
21Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
22Memorial Sloan Kettering Cancer Center, New York, NY
23Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC

Elizabeth K. O'Donnell, MD1, Clifton C Mo, MD2*, Omar Nadeem, MD3, Andrew J. Yee, MD4, Andrew R. Branagan, MD4, Jacob Laubach, MD2, Marilyn T. Gammon, RN5*, Kathleen J. Lively, RN5*, Lisette Packer, RN5*, Cynthia C. Harrington, NP5*, Emerentia Agyemang, NP5*, Jacalyn Rosenblatt, MD6, Nora K. Horick, MS1*, Paul G. Richardson, MD7 and Noopur Raje, MD8

1Massachusetts General Hospital, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
5Massachusetts General Hospital Cancer Center, Boston, MA
6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
7Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
8Mass General Hospital Cancer Center, Boston, MA

Al-Ola Abdallah, MD1, Andrew J Cowan, MD2, Xavier Leleu, MD, PhD3, Cyrille Touzeau4*, Brea Lipe, MD5, Eva Medvedova, MD6, Caitlin Costello, MD7, Jens Hillengass, MD, PhD8, P. Leif Bergsagel, MD9, Raya Mawad, MD10, Henning Schade, MD11*, Daniel Morillo Giles12*, Albert Oriol, MD13*, Yifah Yaron14*, Patrick P Ng14* and Sumit Madan, MD15

1Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
3Department of Oncology, Hematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France
4Hematology Department, Nantes University Hospital, Nantes, France
5Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
6Knight Cancer Institute, Oregon Health and Science University, Portland, OR
7University of California, San Diego, La Jolla, CA
8Roswell Park, Buffalo, NY
9Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
10Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
11Colorado Blood Cancer Institute, Denver, CO
12Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
13Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
14Harpoon Therapeutics, South San Francisco, CA
15Banner MD Anderson Cancer Center at Banner University Medical Center, Phoenix, AZ

Veronica Gonzalez-Calle, MD, PhD1,2*, Paula Rodriguez Otero3,4*, Beatriz Rey-Bua, MD5*, Javier De La Rubia, MD, PhD6*, Felipe De Arriba, PhD7*, Valentin Cabañas, MD8*, Esther González Garcia, MD9*, Enrique M. Ocio10, Cristina Encinas, MD11*, Alexia Suarez Cabrera, PhD12*, Joan Bargay13*, Joaquin Martinez Lopez14*, Marta Sonia Gonzalez, MD15*, Jose Angel Hernandez-Rivas, MD, PhD16*, Laura Rosiñol, MD, PhD17*, Miguel-Teodoro Hernández, MD, PhD18*, Bruno Paiva19*, Maria Teresa Cedena Romero, MD, PhD20*, Noemi Puig, MD, PhD21, Juan-José Lahuerta, MD, PhD22*, Joan Bladé, MD, PhD23*, Jesús San-Miguel, MD, PhD4,19 and Maria-Victoria Mateos, MD21

1Hospital Universitario de Salamanca,Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
2Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
3Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain
4Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
5Hematology Department, University Hospital of Salamanca, Salamanca, Spain
6Hematology Department, Hospital Universitari i Politècnic La Fe, Catholic University of Valencia, Valencia, Spain
7Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
8Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain
9Hospital Universitario de Cabueñes, Gijón, Spain
10Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain, Santander, Spain
11Hematology Department, Hospital General Universitario Gregorio Marañón, MADRID, ESP
12Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas De Gran Canaria, ESP
13Hospital Son Llàtzer, Palma de Mallorca, Spain
14Hospital 12 De Octubre, Complutense University, CNIO, Madrid, Spain
15Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
16Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain
17Hematology, Hematology Department, Hospital Clinic i Provincial, IDIBAPS, Barcelona, Spain
18Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain
19Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
20Hospital 12 de Octubre, Madrid, Spain
21Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
22Hospital Universitario 12 de Octubre; Instituto de Investigación Sanitaria Hospital Universitario 12 de Octubre i+12,H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
23Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

Elena Zamagni1*, Mario Boccadoro, MD2, Andrew Spencer3, Michel Delforge4, Donna E. Reece, MD, FRCPC5, Agoston Gyula Szabo6*, Hermann Einsele, MD7, Evangelos Terpos, MD, PhD8, Fredrik Schjesvold, MD, PhD9, Jelena Bila10*, Christoph Driessen, MD11, Meral Beksac12*, Gordon Cook13*, Cesar Rodriguez, MD14*, Lixia Pei15*, Yingqi Shi15*, Caline Sakabedoyan16*, Jagaoda Jasielec15*, Himal Amin15*, Rachel Kobos15, Pieter Sonneveld, MD17 and Niels WCJ Van De Donk, MD18

1University of Bologna, Bologna, Italy
2University of Turin, Turin, Italy
3Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
4Universitaire Ziekenhuizen Leuven, Leuven, Belgium
5Princess Margaret Cancer Centre, Toronto, ON, Canada
6Rigshospitalet, Copenhagen, Denmark
7Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany
8University of Athens, Athens, Greece
9Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
10University of Belgrade, Belgrade, Serbia
11Kantonsspital St.Gallen, St.Gallen, Switzerland
12Ankara University, Ankara, Turkey
13Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
14Mount Sinai School of Medicine, New York, NY
15Janssen Research & Development, Raritan, NJ
16Janssen-Cilag, Beirut, Lebanon
17Erasmus MC Cancer Institute, Rotterdam, Netherlands
18Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Shaji K Kumar, MD1, Alfred L. Garfall2*, Suzanne Trudel3, Enrique M. Ocio4, Emma Scott5*, Lin Huang5*, Xuewen Ma5*, Yunsi Olyslager6*, Payal Thakkar7*, Lixia Pei7*, Christoph Heuck5* and Evangelos Terpos, MD, PhD8

1Mayo Clinic, Rochester, MN
2Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Princess Margaret Cancer Centre, Toronto, ON, Canada
4Marqués de Valdecilla University Hospital, Santander, Spain
5Janssen Research & Development, Spring House, PA
6Janssen Research & Development, Beerse, Belgium
7Janssen Research & Development, Raritan, NJ
8University of Athens, Athens, Greece

Efstathios Kastritis, MD1*, Giovanni Palladini, MD PhD2, Meletios-Athanasios Dimopoulos, MD, PhD3, Arnaud Jaccard4*, Giampaolo Merlini, MD5, Foteini Theodorakakou, MD6*, Despina Fotiou, MD1*, Monique C. Minnema, MD, PhD7, Ashutosh D. Wechalekar, MD8, Sreeja Varghese, PhD9*, Kyriaki Manousou, MSc10*, Pieter Sonneveld, MD11 and Stefan Schönland12*

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
3Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4CRIBL Lab, HoPital Dupuytren, Limoges Cedex 1, France
5Biotechnology Research Laboratories, Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
6Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
7Department of Hematology, University Medical Center, Utrecht, Netherlands, Utrecht, Netherlands
8Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
9Medical Affairs, Health Data Specialists, Dublin, Ireland
10Health Data Specialists, Dublin, Ireland
11Department of Hematology, ErasmusMC, EMN, Rotterdam, Netherlands
12Department of Internal Medicine V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

Philippe Moreau, MD1*, Thierry Facon2*, Saad Usmani, MD3, Nizar Jacques Bahlis, MD4, Noopur Raje, MD5, Torben Plesner6, Robert Z. Orlowski, MD, PhD7, Supratik Basu8*, Hareth Nahi9*, Cyrille Hulin10*, Hang Quach11, Hartmut Goldschmidt, MD12, Michael O'Dwyer, MD13, Aurore Perrot, MD, PhD14*, Christopher P. Venner15,16*, Katja C. Weisel, MD17, Mourad Tiab18*, Margaret Macro, MD19*, Laurent Frenzel20*, Xavier Leleu, MD, PhD21, Huiling Pei, PhD22*, Maria Krevvata23*, Robin Carson23, Fredrik Borgsten24* and Shaji K Kumar, MD25

1Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
2University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
3Memorial Sloan Kettering Cancer Center, New York, NY
4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
5Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA
6Vejle Hospital and University of Southern Denmark, Vejle, Denmark
7Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
8Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, United Kingdom
9Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
10Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
11University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia
12University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany
13Department of Medicine/Haematology, NUI, Galway, Ireland
14CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France
15Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
16BC Cancer – Vancouver Centre Group, Vancouver, BC, Canada
17Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
18CHD Vendée, La Roche sur Yon, France
19Centre Hospitalier Universitaire (CHU) de Caen, Caen, France
20Hôpital Necker-Enfants Malades, Paris, France
21CHU Poitiers, Hôpital la Milétrie, Poitiers, France
22Janssen Research & Development, LLC, Titusville, NJ
23Janssen Research & Development, LLC, Spring House, PA
24Janssen Research & Development, LLC, Raritan, NJ
25Department of Hematology, Mayo Clinic Rochester, Rochester, MN

Ajay K. Nooka, MD, MPH, FACP1, Adam Cohen, MD2*, Hans C. Lee, MD3, Ashraf Z. Badros, MD4, Attaya Suvannasankha, MD5*, Natalie Callander, MD6, Al-Ola Abdallah, MD7, Suzanne Trudel, MD8*, Ajai Chari, MD9*, Edward Libby, MD10, Maria Chaudhry, MD11*, Malin Hultcrantz, MD, PhD12, Martin Kortuem13*, Paul G. Richardson, MD14, Rakesh Popat15*, Douglas W. Sborov, MD16, Shawn Hakim, PhD17*, Eric Lewis, MD18*, Bharat Bhushan, MSc19*, Boris Gorsh, PharmD17*, Ira Gupta, MD17*, Joanna Opalinska, MD20 and Sagar Lonial, MD21

1Winship Cancer Institute of Emory University Hospital, Atlanta, GA
2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
3Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX
4University of Maryland School of Medicine, Baltimore, MD
5Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN
6Carbone Cancer Center, University of Wisconsin, Madison, WI
7University of Kansas, Kansas City, KS
8Princess Margaret Cancer Centre, Toronto, ON, Canada
9Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
10Division of Medical Oncology, University of Washington, Seattle, WA
11George Washington University, Washington, DC
12Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
13Universitätsklinikum Würzburg, Medizinische Klinik II, Würzburg, Germany
14Dana Farber Cancer Institute, Boston, MA
15University College London Hospitals, NHS Foundation Trust, London, United Kingdom
16University of Utah, Huntsman Cancer Institute, Salt Lake Cty, UT
17GSK, Upper Providence, PA
18GSK, Research Triangle Park, NC
19GSK, Bangalore, India
20GlaxoSmithKline, Collegeville, PA
21Winship Cancer Institute, Emory University, Atlanta, GA

Karen Sweiss, PharmD1, Craig C Hofmeister, MD2, Maria Zappia3*, Maxim Frolov3*, Elizaveta Benevolenskaya3*, John G. Quigley4, Shrihari Kadkol5*, Douglas W. Sborov, MD6, Damiano Rondelli, MD4 and Pritesh Patel4

1Department of Pharmacy Practice, University of Illinois at Chicago, Hinsdale, IL
2Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
3Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL
4Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
5University of Illinois At Chicago, Chicago, IL
6Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT

Suzanne Trudel1, Arleigh McCurdy, MD, BSc2, Molei Fu, MSc3*, Heather J. Sutherland, MD, PhD, FRCPC4, Martha L Louzada, MD, MSc5, Michael P. Chu, MD6, Darrell J White, MD7, Hira S Mian, MD8, Rami Kotb, MD, FRCPC9, Ibraheem Othman, MD, MSc, PhD10, Moustafa Kardjadj, PhD11*, Engin Gul, BSc, MBA12* and Donna E. Reece, MD, FRCPC3

1Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada
2Department of Medicine, Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
3Canadian Myeloma Research Group (CMRG), Vaughan, ON, Canada
4Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
5University of Western Ontario, London Health Sciences Centre, London, ON, Canada
6Department of Oncology, Cross Cancer Institute, Edmonton, AB, Canada
7Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
8Department of Oncology, McMaster University, Hamilton, ON, Canada
9Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
10Allan Blair Cancer Centre, Saskatchewan Cancer Agency, Regina, SK, Canada
11Canadian Myeloma Research Group, Toronto, ON, Canada
12Canadian Myeloma Research Group (CMRG), Concord, ON, Canada

Sabrina L. Browning, MD1, Yuxin Liu, MD1, Terri L. Parker, MD1, Noffar Bar, MD1, Tara Anderson, PA-C2*, Madhav Dhodapkar, MBBS3, Stuart Seropian, MD1, Stephanie Halene, MD1, Mina L Xu, MD4*, Ria Syam, BS1*, Elan Gorshein, DO, JD, MPH5*, Autumn DiAdamo, BS6*, Ashita Talsania, MCRP, MBBS7, Wajih Zaheer Kidwai, MD5, David H. Witt, MD8*, Victor Chang, MD9*, Francesca Montanari, MD10, Andrew Lischuk, MD11*, Wei Wei, MD12*, Andrew Haims, MD11* and Natalia Neparidze, MD1

1Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
2Yale-New Haven Hospital and Yale Cancer Center, New Haven, CT
3Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
4Yale University School of Medicine and Yale Cancer Center, New Haven, CT
5Smilow Cancer Hospital Care Center- Guilford, Yale University School of Medicine and Yale Cancer Center, Guilford, CT
6Department of Genetics, Yale University School of Medicine, New Haven, CT
7Smilow Cancer Hospital Care Center- Torrington, Yale University School of Medicine and Yale Cancer Center, Torrington, CT
8Smilow Cancer Hospital Care Center- Trumbull, Yale University School of Medicine and Yale Cancer Center, Trumbull, CT
9Smilow Cancer Hospital Care Center-Waterbury, Yale University School of Medicine and Yale Cancer Center, Waterbury, CT
10Smilow Cancer Hospital Care Center- Greenwich, Yale University School of Medicine and Yale Cancer Center, Greenwich, CT
11Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT
12Department of Biostatistics, Yale School of Public Health, New Haven, CT

Leon Bernal-Mizrachi, MD1, Ajay K. Nooka, MD, MPH, FACP2, Leonard Heffner, MD3, Craig Emmitt Cole, MD4, Ravi Vij, MD5, J Christine Ye, MD, MSc6, Craig C Hofmeister, MD7, John Rushton, PhD8*, Zhengjia Chen, PhD9*, Subir Goyal, PhD10*, Munevver Cinar, MD11*, Sagar Lonial, MD7 and Jonathan L. Kaufman, MD7

1Grady Health System, Atlanta, GA
2Winship Cancer Institute of Emory University, Atlanta, GA
3Winship Cancer Institute, Emory University, Atlanta, GA
4Karmanos Cancer Insititute, Michigan State University College of Human Medicine, Lansing, MI
5Washington University, St. Louis, MO
6Department of Internal Medicine, Hem/Onc Division, University of Michigan, Ann Arbor, MI
7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
8KSL Biomedical, Buffalo, NY
9Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA
10Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA
11Emory University Winship Cancer Institute/ Department of Hematology and Medical Oncology, Atlanta, GA

Rachid C. Baz, MD1, Jongphil Kim, PhD2*, Christine Sam, MD3, Brandon J. Blue, MD4, Sonila Toska5*, Aaron Collier, BA5*, Jason Brayer, MD, PhD5, Ariel F Grajales-Cruz, MD5, Melissa Alsina, MD**6, Ariosto Siqueira Silva, PhD7* and Kenneth H. Shain, MD, PhD5

1Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL
2Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institutte, Tampa, FL
3Senior Adult Oncology Program, H.Lee Moffitt Cancer Center, Tampa, FL
4Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
5Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
6Moffitt Cancer Center, Tampa, FL
7Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Wilson I. Gonsalves, MD1, Natalia Neparidze, MD2, Jacob B. Allred3*, Shaji K Kumar, MD1, Joel M. Reid, PhD4*, Geoffrey Shapiro, MD, PhD5*, Brian A. Costello, MD4*, Richard Piekarz, MD, PhD, MS, BA6*, Rachid C. Baz, MD7 and Srinivas Devarakonda, MD8

1Division of Hematology, Mayo Clinic, Rochester, MN
2Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
3Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN
4Department of Oncology, Mayo Clinic, Rochester, MN
5Dana-Farber Cancer Institute, Boston
6Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
7Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL
8Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Maria-Victoria Mateos, MD1, Paula Rodriguez Otero, MD, PhD2*, Youngil Koh, MD, PhD3, Joaquin Martinez-Lopez, MD, PhD4*, Gurdeep Parmar, MD5*, H. Miles Prince, MD, FRACP, FRCPA6, Hang Quach7, Paz Ribas, MD8*, Emil Hermansen, MD, PhD9*, Vania T. M. Hungria, MD, PhD10, Sevgi Kalayoglu Besisik, MD11*, Jin Seok Kim, MD, PhD12*, Xavier Leleu, MD, PhD13, Valdas Pečeliūnas, MD, PhD14*, Fredrik Schjesvold, MD, PhD15, Omur G. Sevindik, MD16*, Tatiana Lavrova, MD17*, Franck Dubin, PharmD18*, Christine Devisme, MSc19*, Lucie Lepine, PharmD17*, Sandrine Macé, PhD20*, Mony Morisse, MD, MSc21* and Irene Ghobrial, MD22

1University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
2Servicio de Hematología y Hemoterapia, Clínica Universidad de Navarra, Pamplona, Spain
3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
4H12O-CNIO Clinical Research Unit, CIBERONC, Department of Hematology, Hospital 12 de Octubre, Complutense University, Madrid, Spain
5Illawarra Cancer Care Centre, Wollongong, NSW, Australia
6Cancer Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia
7Clinical Haematology Service, St. Vincent’s Hospital, Melbourne, VIC, Australia
8Department of Hematology, University Hospital La Fe, Valencia, Spain
9Department of Hematology, Zealand University Hospital, Roskilde, Denmark
10Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil
11Department of Internal Medicine, Division of Hematology, Istanbul University Medical Faculty, Istanbul, Turkey
12Division of Hematology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
13Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France
14Hematology, Oncology and Transfusion Medicine Department, Vilnius University Hospital, Vilnius, Lithuania
15Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
16Department of Hematology, Medipol University, Istanbul, Turkey
17Excelya, Boulogne-Billancourt, France
18Sanofi, Research and Development, Vitry-Sur-Seine, France
19Aixial, Boulogne-Billancourt, France
20Sanofi, Vitry-Sur-Seine, France
21Sanofi, Cambridge
22Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Andrew Spencer1, Katrine Fladeland Iversen, MD2*, Binod Dhakal, MBBS3, Maria Creignou, MD4*, Jenny Chen, MD, PhD5, Ida H Hiemstra, PhD6*, Sieto Bosgra, PhD6*, Avani Badani, MD5*, Esther C.W. Breij, PhD6*, Lauren K. Brady, PhD5, A. Kate Sasser, PhD5*, Anders Malmberg, PhD7*, Henrik Gregersen, MD, PhD8*, Markus Hansson, MD, PhD9*, Annemiek Broijl, MD, PhD10*, Maria-Victoria Mateos, MD11 and Torben Plesner2

1Alfred Hospital, Melbourne, Australia
2Vejle Hospital, Vejle, Denmark
3Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
4Department of Hematology, Karolinska University Hospital, Huddinge, Sweden
5Genmab, Princeton, NJ
6Genmab, Utrecht, Netherlands
7Genmab, Copenhagen, Denmark
8Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
9Aalborg University Hospital, Aalborg, Denmark
10Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
11Hospital Universitario Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain

Ruemu E. Birhiray, MD1, Robert M. Rifkin, MD2, Christopher A. Yasenchak, MD3, January Fields-Meehan4*, Roger M. Lyons, MD5, Ramalingham Ratnasabapathy6*, Kimberly Bogard, PharmD7*, Kim Tran7*, Dasha Cherepanov, PhD8*, Stephen J. Noga, MD, PhD7 and Saulius K. Girnius, MD9

1Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN
2Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO
3Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR
4Department of Hematology and Medical Oncology, Kansas City Veterans Affairs Medical Center, Kansas City, MO
5Texas Oncology and US Oncology Research, San Antonio, TX
6Comprehensive Cancer Centers, Henderson, NV
7Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
8Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
9Trihealth Cancer Institute, Cincinnati, OH

Efstathios Kastritis, MD1*, Foteini Theodorakakou, MD2*, Ioannis Ntanasis-Stathopoulos, MD3*, Vasiliki Spiliopoulou, MD3*, Eirini Solia3*, Panagiotis Malandrakis, MD2*, Rodanthi Syrigou, MD3*, Nikoletta-Aikaterini Kokkali3*, Magdalini Migkou, MD3*, Evangelos Eleutherakis Papaiakovou, MD3*, Despina Fotiou, MD2*, Maria Roussou, MD3*, Nikolaos Kanellias, MD4*, Maria Gavriatopoulou, MD2*, Evangelos Terpos, MD, PhD2 and Meletios A. Dimopoulos, MD3

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
2Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
3Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4Department of Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

Cesar Rodriguez, MD1, Katja C. Weisel, MD2, Rachid C. Baz, MD3, Akshanth R. Polepally, PhD4*, Jeremy A. Ross, PhD4*, Ziyi Jin, MS4*, Kristin D'Amico, BS4*, Orlando F. Bueno, MD, PhD5, Leanne Lash Fleming, PhD4* and Peter M. Voorhees, MD6

1Medical Oncology and Hematology, Wake Forest University School of Medicine, Winston-Salem, NC
2Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL
4AbbVie Inc., North Chicago, IL
5AbbVie, Inc., North Chicago, IL
6Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest Baptist, Charlotte, NC

*signifies non-member of ASH